Insider at Enliven Therapeutics (ELVN) files to sell 75,000 shares

Rhea-AI Filing Summary

An Enliven Therapeutics insider, Samuel Kintz, filed notice to sell 75,000 shares of the company’s common stock through Jefferies LLC, with an indicated aggregate market value of $2,004,000.00. The notice lists 59,000,000 common shares outstanding and targets an approximate sale date of 02/17/2026 on Nasdaq.

The 75,000 shares are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. The filing also reports recent sales over the past three months, including 43,743 shares sold on 01/09/2026 for gross proceeds of $1,089,200.70 and 20,000 shares on 01/20/2026 for $535,090.80.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	75000	2004000.00	59000000	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			75000	09/01/2019	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Samuel Kintz 6200 Lookout Road 1st Floor Boulder CO 80301	Enliven Therapeutics	12/17/2025	5000	81892.60
Samuel Kintz 6200 Lookout Road 1st Floor Boulder CO 80301	Enliven Therapeutics	01/08/2026	38757	930261.95
Samuel Kintz 6200 Lookout Road 1st Floor Boulder CO 80301	Enliven Therapeutics	01/09/2026	43743	1089200.70
Samuel Kintz 6200 Lookout Road 1st Floor Boulder CO 80301	Enliven Therapeutics	01/20/2026	20000	535090.80
Samuel Kintz 6200 Lookout Road 1st Floor Boulder CO 80301	Enliven Therapeutics	02/06/2026	5000	145180.20

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for ELVN disclose?

The Form 144 discloses an insider’s intent to sell 75,000 Enliven Therapeutics (ELVN) common shares through Jefferies LLC. The planned sale has an indicated aggregate market value of $2,004,000.00 and is expected to occur around 02/17/2026 on Nasdaq.

Who is selling Enliven Therapeutics (ELVN) shares and how many?

The notice identifies Samuel Kintz as the seller for whose account the securities are to be sold. He plans to sell 75,000 Enliven Therapeutics common shares, which are described as founder shares originally acquired on 09/01/2019 from Enliven Therapeutics.

What recent ELVN stock sales by the insider does the filing list?

The filing lists several recent sales by Samuel Kintz, including 43,743 Enliven Therapeutics shares on 01/09/2026 for gross proceeds of $1,089,200.70, and 20,000 shares on 01/20/2026 for gross proceeds of $535,090.80, plus other smaller transactions.

What is the approximate market value of the ELVN shares to be sold?

The 75,000 Enliven Therapeutics common shares covered by the Form 144 have an indicated aggregate market value of $2,004,000.00. This value is based on the information provided in the notice, which also identifies Nasdaq as the intended trading venue.

How many Enliven Therapeutics (ELVN) shares are shown as outstanding?

The Form 144 indicates that 59,000,000 Enliven Therapeutics common shares are outstanding. This figure provides context for the planned sale of 75,000 shares but is a baseline capital figure rather than the amount being sold under the notice.

When and how did the insider acquire the ELVN shares being sold?

The shares to be sold are identified as Common founder shares acquired on 09/01/2019 from Enliven Therapeutics. The table shows 75,000 securities acquired on that date with the nature of acquisition listed as “Founder Shares” and payment noted as “n/a.”